Albemarle (NYSE:ALB) shares down 1.2% on analyst downgrade

VaselineAugust 10, 2024

0 4 minutes read

Albemarle Co. shares. (NYSE:ALB – Get Free Report ) traded up 1.2% on Friday after Piper Sandler cut their price target on the stock from $95.00 to $90.00. Piper Sandler currently has an underweight rating on the stock. Albemarle traded as high as $80.10 and last traded at $80.88. During trading, 417,493 shares were traded, down 86% from the session’s average volume of 3,078,234 shares. Shares previously closed at $81.83.

Other research analysts have recently issued research reports on the company. Royal Bank of Canada cut their price objective on Albemarle from $128.00 to $111.00 and set an “outperform” rating for the company in a research note on Tuesday. KeyCorp cut their price target on Albemarle from $151.00 to $132.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Mizuho decreased their price objective on Albemarle from $128.00 to $103.00 in a report on Wednesday, July 31st. Robert W. Baird lowered Albemarle from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $102.00 to $85.00 in a research report on Monday, 5 August. Finally, Baird RW lowered Albemarle from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 5th. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $128.11, according to MarketBeat.com.

Read our latest report on ALB

Indoor activity

Want more great investment ideas?

In other Albemarle news, CAO John Clarence Barichivich III sold 1,475 shares of Albemarle stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $132.17, for a total value of $194,950.75. Following the completion of the transaction, the chief accounting officer now directly owns 4,743 shares of the company’s stock, valued at $626,882.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed via this link. In related news, CAO John Clarence Barichivich III sold 1,475 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $132.17, for a total value of $194,950.75. Following the transaction, the chief accounting officer now owns 4,743 shares of the company’s stock, valued at approximately $626,882.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Mark Richard Mummert sold 843 shares of Albemarle stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $135.53, for a total transaction of $114,251.79. Following the completion of the transaction, the senior vice president now directly owns 6,802 shares in the company, valued at approximately $921,875.06. The disclosure for this sale can be found here. Corporate insiders own 0.38% of the company’s shares.

Institutional inputs and outputs

A number of hedge funds have recently made changes to their positions in the company. Prime Capital Investment Advisors LLC boosted its holdings in shares of Albemarle by 23.2% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 3,078 shares of the specialty chemicals company’s stock valued at $445,000 after purchasing an additional 580 shares in the last quarter. International Assets Investment Management LLC raised its position in Albemarle by 4.8% during the 4th quarter. International Assets Investment Management LLC now owns 2,407 shares of the specialty chemicals company’s stock worth $348,000 after buying an additional 111 shares. shares in the last quarter. RFG Advisory LLC raised its position in Albemarle by 58.6% during the 4th quarter. RFG Advisory LLC now owns 4,059 shares of the specialty chemicals company’s stock worth $586,000 after acquiring an additional 1,499 shares in the last quarter. Sequoia Financial Advisors LLC acquired a new position in Albemarle in the 4th quarter valued at approximately $363,000. Finally, Cerity Partners LLC increased its position in Albemarle by 27.2% during the 4th quarter. Cerity Partners LLC now owns 25,176 shares of the specialty chemicals company’s stock worth $3,637,000 after acquired an additional 5,376 shares in the last quarter. Hedge funds and other institutional investors own 92.87% of the company’s shares.

Albemarle stock performance

The company has a current ratio of 2.67, a quick ratio of 1.91, and a debt-to-equity ratio of 0.38. The firm has a 50 day simple moving average of $97.72 and a two hundred day simple moving average of $114.16. The company has a market cap of $9.60 billion, a price-to-earnings ratio of 29.69, a price-to-earnings-growth ratio of 3.48 and a beta of 1.57.

Albemarle (NYSE:ALB – Get Your Free Report ) last announced its earnings results on Wednesday, July 31st. The specialty chemicals company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.53 by ($0.49). The company had revenue of $1.43 billion for the quarter, compared to the consensus estimate of $1.34 billion. Albemarle had a negative net margin of 6.72% and a positive return on equity of 6.38%. Albemarle’s revenue for the quarter was down 39.7% compared to the same quarter last year. In the same quarter last year, the company earned $7.33 EPS. As a group, sell-side analysts forecast that Albemarle Co. will post 1.67 earnings per share for the current fiscal year.

Albemarle increases dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 1st. Investors of record on Friday, September 13th will be issued a $0.405 dividend. This represents a dividend of $1.62 on an annualized basis and a yield of 1.98%. The ex-dividend date is Friday, September 13. This is an increase from Albemarle’s previous quarterly dividend of $0.40. Albemarle’s dividend payout ratio is currently 58.91%.

Albemarle Company Profile

(Get a free report)

Albemarle Corporation develops, manufactures and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The energy storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide and lithium chloride; Technical services for the handling and use of reactive lithium products; and recycling services for by-products containing lithium.